Novo Nordisk was the first to market with a GLP-1 weight-loss shot, but lost its lead to Eli Lilly.
Given the size of the weight-loss market, there's likely to be room for more than one GLP-1 maker.
Novo Nordisk's GLP-1 pill has been a huge success, as the company shifts to a volume-driven model.
Shares of Novo Nordisk (NYSE:NVO) have fallen 70% from the all-time highs reached after it launched the first GLP-1 weight-loss shot. That has pushed the dividend yield up to 4.5%, well above the pharmaceutical industry average of 1.3%, despite a strong payout ratio of roughly 33%.
Wall Street may not be giving Novo Nordisk enough credit, especially given the strength of its new GLP-1 pill. Here's why more aggressive investors may want to jump on this high-yield opportunity.
Missed AI’s "Act 1"? Act 2 Could Be 15x Bigger. Most investors think they missed the AI boat because they didn't buy Nvidia in 2005. But according to our analysts, we’re only at the end of "Act 1"—the R&D phase. "Act 2" is the global rollout. Continue »
Image source: Novo Nordisk.
There's no way to sugarcoat it: Novo Nordisk flubbed the launch of its Wegovy GLP-1 shot. The product was very well received, but the drug maker couldn't keep up with demand. That allowed generics to enter the market early, creating a major competitive headwind. When Eli Lilly (NYSE:LLY) introduced a more effective GLP-1 shot, Novo Nordisk quickly became the number two player. Investors' early enthusiasm quickly turned into deep pessimism.
That pessimism persists, even after Novo Nordisk's successful launch of a Wegovy pill. Consumers prefer pills over shots, for obvious reasons. That helps explain why Novo Nordisk's pill launch has been even more successful than its GLP-1 shot launch. In fact, in the third quarter, the company estimates that the Wegovy pill captured eight out of 10 new patients starting oral GLP-1 weight-loss treatments.
The company is executing so well that it increased its full-year 2026 sales and earnings guidance when it reported third-quarter results. From this perspective, Wall Street may be overly negative about the business.
But there's another problem that investors are grappling with. Novo Nordisk is moving to a volume-driven business model. That involves lowering prices, which has been a headwind for the top and bottom lines. In fact, while the company updated its guidance, the sales and revenue midpoint is now flat. That's a massive improvement from the previous midpoint of down 3% for both metrics, but it is understandable that investors would remain concerned.
Essentially, Novo Nordisk needs to prove not only that it remains an innovative drugmaker but also that its volume-driven model is working. And given the intensely competitive healthcare sector, it will likely see additional GLP-1 competition at some point. For example, Pfizer (NYSE:PFE) is hard at work on an acquired long-acting GLP-1 drug it purchased after the company dropped an internal GLP-1 candidate. That said, the global obesity market is very large, so there's likely to be plenty of room for more than one player. And there are also opportunities for companies to fill different niches within the still emerging GLP-1 market.
For more aggressive dividend investors, the risk/reward balance is likely tilted toward reward with Novo Nordisk. The value opportunity here isn't just highlighted by the lofty yield. The stock's price-to-sales ratio of 3.3x is well below its five-year average of 8x. Its price-to-earnings ratio of roughly 10x is far lower than the five-year average of 23x. And Novo Nordisk's price-to-book ratio of 5.2x is a fraction of its 15x longer-term average. Notably, all of the ratios are lower than they were before the launch of the Wegovy shot. For reference, Eli Lilly's P/E ratio is nearly 45x.
Given the success Novo Nordisk is seeing with its Wegovy pill and the improved revenue and earnings outlook, it seems like management is executing well as it shifts to a volume-driven model. Add in the lofty yield and attractive valuation, and the story gets even more attractive. If you can handle a little uncertainty, this well-run drug maker is probably worth a very close look right now.
Before you buy stock in Novo Nordisk, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Novo Nordisk wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $305,941!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $771,325!*
Now, it’s worth noting Stock Advisor’s total average return is 719% — a market-crushing outperformance compared to 192% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of November 21, 2026.
Reuben Gregg Brewer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Eli Lilly, Novo Nordisk, and Pfizer. The Motley Fool has a disclosure policy.